208 related articles for article (PubMed ID: 28317290)
1. The effect of engagement in an HIV/AIDS integrated health programme on plasma HIV-1 RNA suppression among HIV-positive people who use illicit drugs: a marginal structural modelling analysis.
Ti L; Dong H; Kerr T; Turje RB; Parashar S; Min JE; Montaner J; Wood E; Milloy MJ
HIV Med; 2017 Sep; 18(8):580-586. PubMed ID: 28317290
[TBL] [Abstract][Full Text] [Related]
2. Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting.
Loh J; Kennedy MC; Wood E; Kerr T; Marshall B; Parashar S; Montaner J; Milloy MJ
AIDS Care; 2016 Nov; 28(11):1448-54. PubMed ID: 27248328
[TBL] [Abstract][Full Text] [Related]
3. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada.
Lake S; Kerr T; Capler R; Shoveller J; Montaner J; Milloy MJ
Int J Drug Policy; 2017 Apr; 42():63-70. PubMed ID: 28336000
[TBL] [Abstract][Full Text] [Related]
4. Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting.
Richardson LA; Kerr TH; Dobrer S; Puskas CM; Guillemi SA; Montaner JS; Wood E; Milloy MJ
AIDS; 2015 Nov; 29(18):2487-95. PubMed ID: 26558546
[TBL] [Abstract][Full Text] [Related]
5. Social and structural factors associated with greater time with a plasma HIV-1 RNA viral load above log10(1500) copies/ml among illicit drug users.
Kennedy MC; Kerr TH; Wood E; Shoveller JA; Montaner JSG; Milloy MS
AIDS; 2018 May; 32(8):1059-1067. PubMed ID: 29424782
[TBL] [Abstract][Full Text] [Related]
6. Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting.
Milloy MJ; King A; Kerr T; Adams E; Samji H; Guillemi S; Wood E; Montaner J
J Int AIDS Soc; 2016; 19(1):20617. PubMed ID: 27094914
[TBL] [Abstract][Full Text] [Related]
7. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.
Liang J; Nosova E; Reddon H; Nolan S; Socías E; Barrios R; Milloy MJ
AIDS; 2020 Jul; 34(9):1389-1396. PubMed ID: 32590435
[TBL] [Abstract][Full Text] [Related]
9. Residential Eviction and Risk of Detectable Plasma HIV-1 RNA Viral Load Among HIV-Positive People Who Use Drugs.
Kennedy MC; Kerr T; McNeil R; Parashar S; Montaner J; Wood E; Milloy MJ
AIDS Behav; 2017 Mar; 21(3):678-687. PubMed ID: 26906022
[TBL] [Abstract][Full Text] [Related]
10. Dispensation of antiretroviral therapy and methadone maintenance therapy at the same facility in a low-barrier setting linked to optimal adherence to HIV treatment.
Mohd Salleh NA; Fairbairn N; Nolan S; Barrios R; Shoveller J; Richardson L; Milloy MJ
HIV Med; 2019 Oct; 20(9):606-614. PubMed ID: 31359615
[TBL] [Abstract][Full Text] [Related]
11. Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative.
Milloy MJ; Wood E; Kerr T; Hogg B; Guillemi S; Harrigan PR; Montaner J
Clin Infect Dis; 2016 Mar; 62(5):640-7. PubMed ID: 26553011
[TBL] [Abstract][Full Text] [Related]
12. Estimating the minimum antiretroviral adherence required for plasma HIV-1 RNA viral load suppression among people living with HIV who use unregulated drugs.
Stover S; Milloy MJ; Grant C; Fairbairn N; Socías ME
AIDS; 2022 Jul; 36(9):1233-1243. PubMed ID: 35833680
[TBL] [Abstract][Full Text] [Related]
13. Impact of supervised drug consumption services on access to and engagement with care at a palliative and supportive care facility for people living with HIV/AIDS: a qualitative study.
McNeil R; Dilley LB; Guirguis-Younger M; Hwang SW; Small W
J Int AIDS Soc; 2014; 17(1):18855. PubMed ID: 24629844
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.
Yeung B; Mohd Salleh NA; Socías E; Dong H; Shoveller J; Montaner JSG; Milloy MS
AIDS Behav; 2019 May; 23(5):1250-1257. PubMed ID: 30284081
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study.
Hayashi K; Wood E; Kerr T; Dong H; Nguyen P; Puskas CM; Guillemi S; Montaner JS; Milloy MJ
BMC Infect Dis; 2016 Aug; 16(1):455. PubMed ID: 27568002
[TBL] [Abstract][Full Text] [Related]
16. Association between public injecting and drug-related harm among HIV-positive people who use injection drugs in a Canadian setting: A longitudinal analysis.
Ickowicz S; Wood E; Dong H; Nguyen P; Small W; Kerr T; Montaner JSG; Milloy MJ
Drug Alcohol Depend; 2017 Nov; 180():33-38. PubMed ID: 28865390
[TBL] [Abstract][Full Text] [Related]
17. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis.
Milloy MJ; Kerr T; Salters K; Samji H; Guillemi S; Montaner J; Wood E
BMC Infect Dis; 2013 Dec; 13():565. PubMed ID: 24289651
[TBL] [Abstract][Full Text] [Related]
18. Criminal Justice System Involvement as a Risk Factor for Detectable Plasma HIV Viral Load in People Who Use Illicit Drugs: A Longitudinal Cohort Study.
Ickowicz S; Salleh NAM; Fairbairn N; Richardson L; Small W; Milloy MJ
AIDS Behav; 2019 Sep; 23(9):2634-2639. PubMed ID: 31236749
[TBL] [Abstract][Full Text] [Related]
19. An integrated approach to care attracts people living with HIV who use illicit drugs in an urban centre with a concentrated HIV epidemic.
Fernando S; McNeil R; Closson K; Samji H; Kirkland S; Strike C; Turje RB; Zhang W; Hogg RS; Parashar S
Harm Reduct J; 2016 Nov; 13(1):31. PubMed ID: 27876048
[TBL] [Abstract][Full Text] [Related]
20. Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.
McKinnon E; Castley A; Payne L; Pummer S; Nolan D
HIV Med; 2016 Aug; 17(7):495-504. PubMed ID: 26537660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
